Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Alzheimer’s disease and related dementias

The Amyloid-β Pathway in Alzheimer's Disease.

Harald Hampel; John Hardy; Kaj Blennow; Christopher Chen; George Perry; Seung Hyun Kim; Victor L Villemagne; Paul Aisen; Michele Vendruscolo; Takeshi Iwatsubo; Colin L Masters; Min Cho; Lars Lannfelt; Jeffrey L Cummings; Andrea Vergallo

Originally published in Molecular psychiatry · 2021-08-30

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular mechanisms of the pathway and the spatial-temporal dynamics leading to synaptic failure, neurodegeneration, and clinical onset are still under intense investigation, the established biochemical alterations of the Aβ cycle remain the core biological hallmark of AD and are promising targets for the development of disease-modifying therapies. Here, we systematically review and update the vast state-of-the-art literature of Aβ science with evidence from basic research studies to human genetic and multi-modal biomarker investigations, which supports a crucial role of Aβ pathway dyshomeostasis in AD pathophysiological dynamics. We discuss the evidence highlighting a differentiated interaction of distinct Aβ species with other AD-related biological mechanisms, such as tau-mediated, neuroimmune and inflammatory changes, as well as a neurochemical imbalance.

Conclusions

Over the recent decades, translational and multi-disciplinary studies—from (epi)genetic, to biological, and to biomarker-based clinical investigations—have contributed to unveiling the biochemical, physiological, and pathophysiological features of the Aβ pathway, including its spatial and temporal dynamics throughout the AD continuum. All point to the Aβ pathway as a hallmark of disease pathophysiology rather than a passive readout of the disease process.

Editorial reading guide

  • Was the evidence cross-sectional, longitudinal or experimental?
  • How did the authors account for age, disease stage and differences among participants?